NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 186)
Posted On: 09/02/2022 3:51:31 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD, as the newest member of its board. Turkel brings more than two decades of experience as an executive-level leader in both start-up and mid-size pharma/biotech companies. As founder and CEO of Nezee Therapeutics, she gained critical expertise and insight in the space; she also served as president and head of research and development Novus Therapeutics, which was later renamed Eledon Pharmaceuticals Inc. (NASDAQ: ELDN). Currently she serves as an independent board director at Object Pharma and advisory committee member at nonprofit Prostate Cancer Research; she is also a dean advisor at Chapman University School of Pharmacy. In her various roles, Turkey has led and executed FDA registration and commercial strategic plans as well as global development programs; she has invaluable experience in a range of sectors, including neurosciences, pain, cardiovascular, psychiatry, rare diseases, ophthalmology, aesthetics, urology and otology therapeutic areas. In addition, Turkel designed and led an innovative BOTOX(R) chronic migraine registration program for Allergan, now AbbVie Inc. (NYSE: ABBV), which generated more than a billion dollars. “Lexaria is delighted to welcome Dr. Turkel as we continue to position the company for advancement following our recent successful pre-IND meeting with the Food and Drug Administration,” said Lexaria board chair Chris Bunka in the press release. “Catherine’s practical development and regulatory expertise will be of increasing value to Lexaria, and we look forward to working with her.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD, as the newest member of its board. Turkel brings more than two decades of experience as an executive-level leader in both start-up and mid-size pharma/biotech companies. As founder and CEO of Nezee Therapeutics, she gained critical expertise and insight in the space; she also served as president and head of research and development Novus Therapeutics, which was later renamed Eledon Pharmaceuticals Inc. (NASDAQ: ELDN). Currently she serves as an independent board director at Object Pharma and advisory committee member at nonprofit Prostate Cancer Research; she is also a dean advisor at Chapman University School of Pharmacy. In her various roles, Turkey has led and executed FDA registration and commercial strategic plans as well as global development programs; she has invaluable experience in a range of sectors, including neurosciences, pain, cardiovascular, psychiatry, rare diseases, ophthalmology, aesthetics, urology and otology therapeutic areas. In addition, Turkel designed and led an innovative BOTOX(R) chronic migraine registration program for Allergan, now AbbVie Inc. (NYSE: ABBV), which generated more than a billion dollars. “Lexaria is delighted to welcome Dr. Turkel as we continue to position the company for advancement following our recent successful pre-IND meeting with the Food and Drug Administration,” said Lexaria board chair Chris Bunka in the press release. “Catherine’s practical development and regulatory expertise will be of increasing value to Lexaria, and we look forward to working with her.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼